Forward or Backward: Lessons Learned from Small Molecule Drugs Approved by FDA from 2012 to 2022
Molecules · 05.12.2023 · 28 (24) · 7941
DOI: 10.3390/molecules28247941 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 05.12.2023. Verfasst von Mingxiao Gu und 3 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009…. Hauptthemen laut MEDLINE: Drug Approval, Drug Development. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Project Program of State Key Laboratory of Natural Medicines (China Pharmaceutical University), Young Elite Scientists Sponsorship Program by CAST.
Abstract (Originalsprache)
At every juncture in history, the design and identification of new drugs pose significant challenges. To gain valuable insights for future drug development, we conducted a detailed analysis of New Molecular Entitiy (NME) approved by the Food and Drug Administration (FDA) from 2012 to 2022 and focused on the analysis of first-in-class (FIC) small-molecules from a perspective of a medicinal chemist. We compared the change of numbers between all the FDA-approved NMEs and FIC, which could be more visual to analyze the changing trend of FIC. To get a more visual change of molecular physical properties, we computed the annual average trends in molecular weight for FIC across various therapeutic fields. Furthermore, we consolidated essential information into three comprehensive databases, which covered the indications, canonical SMILES, structural formula, research and development (R&D) institutions, molecular weight, calculated LogP (CLogP), and route of administration on all the small-molecule pharmaceutical. Through the analysis of the database of 11 years of approvals, we forecast the development trend of NME approval in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.
- Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
ORCID-Profile: Mingxiao Gu, Qidong You, Lei Wang
Förderung
- National Natural Science Foundation of China
- Project Program of State Key Laboratory of Natural Medicines (China Pharmaceutical University)
- Young Elite Scientists Sponsorship Program by CAST
- National Innovation and Entrepreneurship Training Program for Undergraduate
Zitieren
APA
Gu, M., Sun, S., You, Q., & Wang, L. (2023). Forward or Backward: Lessons Learned from Small Molecule Drugs Approved by FDA from 2012 to 2022. Molecules, 28(24), 7941. https://doi.org/10.3390/molecules28247941
Vancouver
Gu M, Sun S, You Q, Wang L. Forward or Backward: Lessons Learned from Small Molecule Drugs Approved by FDA from 2012 to 2022. Molecules. 2023;28(24):7941. doi:10.3390/molecules28247941
BibTeX
@article{Gu2023,
author = {Gu, Mingxiao and Sun, Sudan and You, Qidong and Wang, Lei},
title = {Forward or Backward: Lessons Learned from Small Molecule Drugs Approved by FDA from 2012 to 2022},
journal = {Molecules},
year = {2023},
volume = {28},
number = {24},
pages = {7941},
doi = {10.3390/molecules28247941}
}
EUVIMED